MaurizioFavaMD

Psychopharmacology

Psychiatrist-in-Chief, Massachusetts General Hospital (MGH), Director, Division of Clinical Research of the MGH Research Institute; Slater Family Professor of Psychiatry, Harvard Medical School; Executive Director, MGH Clinical Trials Network and Institute

Join to view full profile

Dr. Fava is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Fava's full profile

Already have an account?

Office
55 Fruit St
Boston, MA 02114
Phone+1 617-724-0838

Fax+1 617-726-2688

Education & Training

Massachusetts General Hospital/McLean HospitalResidency, Psychiatry, 1985 - 1988
University of Padua College of MedicineClass of 1982

Certifications & Licensure

WA State Medical License 1984 - 2026
MA State Medical License 1988 - 2025
American Board of Psychiatry and Neurology Psychiatry

Awards, Honors, & Recognition

Top MD Consumers Checkbook

Clinical Trials

Safety and Effectiveness of S-adenosyl-l-methionine (SAMe) for the Treatment of Major Depression Start of enrollment: 2005 Apr 01
Completed
Not Applicable
Bupropion as an Adjunct to the Nicotine Patch Plus CBT Start of enrollment: 1999 Apr 01
Completed
Phase 4
Effectiveness of GW468816, an NMDA Glycine Site Antagonist, for Prevention of Relapse to Smoking Start of enrollment: 2006 Aug 01
Completed
Phase 2
Prozac Treatment of Major Depression: Discontinuation Study Start of enrollment: 1995 Nov 01
Completed
Phase 4
A Double-Blind, Placebo-Controlled Study of Aripiprazole Adjunctive to Antidepressant Therapy Start of enrollment: 2008 Sep 01
Completed
Phase 3
Efficacy and Safety Study of a Combination Product [Drug:BCI-024 (Buspirone) and Drug:BCI-049 (Melatonin)] to Treat Major Depressive Disorder (MDD) Start of enrollment: 2008 May 01
Completed
Phase 2
Open Label Extension Assessing the Tolerability of BCI-024 in Combination With BCI-049 in Patients With Major Depressive Disorder (MDD) Start of enrollment: 2008 Jul 01
Completed
Phase 2
Pilot Study of Open-label Placebo to Treat Major Depressive Disorder Start of enrollment: 2010 May 01
Completed
Phase 2
Effectiveness of GSK598809, a Selective D3 Antagonist, Added to CBT and NRT for Smoking Cessation and Relapse Prevention Start of enrollment: 2010 Aug 01
Completed
Phase 2
Efficacy and Tolerability of Riluzole in Treatment Resistant Depression Start of enrollment: 2011 Jun 01
Completed
Phase 2
A Study of the Use of IV Scopolamine to Augment the Efficacy of Electroconvulsive Therapy (ECT) Start of enrollment: 2010 Apr 01
Terminated
Phase 2
Study of Probiotic GanedenBC30 for Irritable Bowel Syndrome and Major Depressive Disorder Start of enrollment: 2011 Jun 01
Terminated
Phase 4
Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care for Depression Start of enrollment: 2011 Jul 29
Completed
Phase 2
Adaptation of Dialectical Behavior Therapy Skills-Groups for Individuals With Suicidal Ideation and Depression Start of enrollment: 2011 Oct 01
Completed
Not Applicable
Iloperidone Augmentation of SSRIs for Patients With Major Depressive Disorder With Residual Anger and Irritability Start of enrollment: 2012 Apr 01
Completed
Phase 4
Stimulant Enhancement of Well-Being Therapy for Depression Start of enrollment: 2012 Feb 01
Terminated
Not Applicable
A Safety and Cognitive Function Study of EVP-6124 Versus Placebo in Subjects With Nicotine Dependence Start of enrollment: 2011 Dec 01
Terminated
Phase 2
Trial of Low Field Magnetic Stimulation Augmentation of Antidepressant Therapy in Treatment-Resistant Depression Start of enrollment: 2013 Apr 01
Completed
Not Applicable
Testosterone Antidepressant Augmentation in Women Start of enrollment: 2013 Aug 01
Completed
Not Applicable
Proof-of-Concept Trial of CERC-501 Augmentation of Antidepressant Therapy in Treatment-Resistant Depression Start of enrollment: 2013 Sep 12
Terminated
Phase 2
A Proof of Concept Study of Intravenous Sodium Nitroprusside in Adults With Symptomatic Schizophrenia Start of enrollment: 2015 May 01
Completed
Phase 2
Sequential Therapy for the Treatment of Severe Bipolar Depression. Start of enrollment: 2018 Jan 15
Completed
Phase 2
A Study of Brexpiprazole Plus Ketamine in Treatment-Resistant Depression (TRD) Start of enrollment: 2017 Sep 14
Completed
Phase 4
Join now to see all

Publications & Presentations

PubMed

862 citations
Reduced Caudate and Nucleus Accumbens Response to Rewards in Unmedicated Individuals With Major Depressive Disorder
Diego A. Pizzagalli, Avram J. Holmes, Daniel G. Dillon, B.A. Elena L. Goetz, B.A. Jeffrey L. Birk
The American Journal of Psychiatry. 2009-06-01
316 citations
Genome-wide association for major depressive disorder: a possible role for the presynaptic protein piccolo
Patrick F. Sullivan, E.J.C. de Geus, Gonneke Willemsen, Michael R. James, Jan Smit
Molecular Psychiatry. 2009-04-01
113 citations
Strengthening clinical effectiveness trials: Equipoise-stratified randomization
Philip W. Lavori, A. John Rush, Stephen R. Wisniewski, Jonathan E. Alpert, Maurizio Fava
Biological Psychiatry. 2001-11-15

Journal Articles

Research Paper Tachyphylaxis in Major Depressive Disorder: A Review of the Current State of Research
Gustavo Kinrys, Andrew A Nierenberg, George I Papakostas, David Mischoulon, Maurizio Fava, Marlene P Freeman, ScienceDirect
Research Paper Understanding the Effects of Emotional Reactivity on Depression and Suicidal Thoughts and Behaviors: Moderating Effects of Childhood Adversity and Resil...
Benjamin G Shapero, Daphne J Holt, Amy Farabaugh, Joey C Cheung, Maurizio Fava, ScienceDirect
Can Electronic Health Records Revive Central Nervous System Clinical Trials?
Maurizio Fava, Roy H Perlis, Nature
Opioid System Modulation with buprenorphine/samidorphan Combination for Major Depressive Disorder: Two Randomized Controlled Studies
Michael E Thase, Madhukar H Trivedi, Maurizio Fava, Nature
Double-Blind, Placebo-Controlled, Dose-Ranging Trial of Intravenous Ketamine as Adjunctive Therapy in Treatment-Resistant Depression (TRD)
Sanjay J Mathew, Madhukar H Trivedi, Lee C Chang, Dan V Iosifescu, Manish K Jha, Maurizio Fava, Marlene P Freeman, Cristina Cusin, James Murrough, George I Papakostas,..., Nature
Pretreatment and Early-Treatment Cortical Thickness Is Associated with SSRI Treatment Response in Major Depressive Disorder
Elizabeth A Bartlett, Jie Yang, Benji T Kurian, Madhukar Trivedi, Ramin V Parsey, Myrna Weissman, Maurizio Fava, Joseph M Trombello, Melvin McInnis, Nature
Join now to see all

Lectures

Strategies for the Treatment of Anxious Depression
162nd Annual Meeting, San Francisco, California, USA
Strategies for the Treatment of Anxious Depression
American Psychiatric Association, 162nd Annual Meeting, San Francisco, California, USA

Authored Content

S132. Cerebral Blood Perfusion Predictors of Antidepressant Response in Major Depressive DisorderApril 2018
S131. Resting State Functional Connectivity Patterns Differentially Predict Treatment Outcomes to Sertraline Versus Placebo in Patients with Major Depressive DisorderApril 2018
S132. Cerebral Blood Perfusion Predictors of Antidepressant Response in Major Depressive DisorderApril 2018
S131. Resting State Functional Connectivity Patterns Differentially Predict Treatment Outcomes to Sertraline Versus Placebo in Patients with Major Depressive DisorderApril 2018
Characterizing Anxiety Subtypes and the Relationship to Behavioral Phenotyping in Major Depression: Results from the EMBARC StudyApril 2018
Characterizing Anxiety Subtypes and the Relationship to Behavioral Phenotyping in Major Depression: Results from the EMBARC StudyApril 2018
Join now to see all

Press Mentions

ABVC BioPharma Provides 2023 Pipeline UpdateFebruary 28th, 2023
Relmada Therapeutics Announces Top-Line Results from Phase 3 RELIANCE III Trial for REL-1017 as a Monotherapy for the Treatment of Major Depressive DisorderOctober 13th, 2022
Relmada Shares Collapse After Fast-Acting Depression Drug Fails First TestOctober 13th, 2022
Join now to see all